Caris Life Sciences (NASDAQ:CAI) Hits New 52-Week Low After Analyst Downgrade

Key Points

• Caris Life Sciences hit a new 52-week low after Citigroup cut its price target to $28 from $35, with shares trading as low as $15.71 and last near $16.15.
• Several analysts trimmed targets after the company’s recent results, including JPMorgan to $30 and BTIG to $32, though most still kept bullish ratings; the stock’s consensus rating remains Moderate Buy.
• Despite the stock slide, Caris reported strong fundamentals, including Q1 2026 revenue up 79% year over year to $216.2 million and recent progress toward expanding Caris Assure blood-based testing into New York.

Shares of Caris Life Sciences, Inc. (NASDAQ:CAI - Get Free Report) hit a new 52-week low during trading on Saturday after Citigroup lowered their price target on the stock from $35.00 to $28.00. Citigroup currently has a buy rating on the stock. Caris Life Sciences traded as low as $15.71 and last traded at $16.15, with a volume of 8867526 shares. The stock had previously closed at $19.84.

Several other equities research analysts also recently issued reports on the stock. Piper Sandler assumed coverage on shares of Caris Life Sciences in a research report on Friday, April 10th. They set a "neutral" rating and a $21.00 price objective for the company. Wall Street Zen cut shares of Caris Life Sciences from a "buy" rating to a "hold" rating in a research report on Saturday, May 2nd. BTIG Research lowered their target price on Caris Life Sciences from $38.00 to $32.00 and set a "buy" rating for the company in a report on Friday. JPMorgan Chase & Co. dropped their price target on Caris Life Sciences from $35.00 to $30.00 and set an "overweight" rating on the stock in a research note on Friday. Finally, Robert W. Baird set a $22.00 price target on Caris Life Sciences in a report on Friday. Six analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $27.56.

Key Stories Impacting Caris Life Sciences

Here are the key news stories impacting Caris Life Sciences this week:

• Positive Sentiment: Caris reported strong Q1 2026 results, with total revenue rising 79% year over year to $216.2 million, signaling continued demand for its molecular profiling services. Caris Life Sciences Reports First Quarter 2026 Financial Results
• Positive Sentiment: The company submitted an application to New York State health regulators for authorization to perform Caris Assure blood-based testing on New York specimens, a potentially meaningful commercial expansion for its diagnostic platform. Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure Blood-Based Testing Authorization
• Positive Sentiment: Despite lowering price targets, Citigroup, JPMorgan, and BTIG all kept bullish ratings on CAI, suggesting analysts still see substantial upside from current levels. Benzinga analyst update
• Neutral Sentiment: Investors are still parsing the earnings call transcript and presentation for details on profitability, margin trends, and whether management’s full-year guidance is achievable. Caris (CAI) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Coverage focused on why the stock is down reflects broader concern that valuation remains elevated and that the market may be reacting more to expectations and guidance than to the strong revenue beat. Why Caris Life Sciences, Inc.’s (CAI) Stock Is Down 18.04%
• Negative Sentiment: Multiple analysts cut their price targets after the report, including Citigroup to $28, JPMorgan to $30, and BTIG to $32, which may have weighed on sentiment even though all maintained positive ratings. Analyst price target changes

Institutional Trading of Caris Life Sciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. UBS Group AG boosted its position in Caris Life Sciences by 825.9% during the fourth quarter. UBS Group AG now owns 2,183,980 shares of the company's stock valued at $58,924,000 after purchasing an additional 1,948,107 shares during the last quarter. Zevenbergen Capital Investments LLC acquired a new position in shares of Caris Life Sciences during the 4th quarter worth approximately $14,655,000. DekaBank Deutsche Girozentrale bought a new stake in shares of Caris Life Sciences during the 4th quarter worth approximately $3,942,000. Hamilton Lane Advisors LLC acquired a new stake in shares of Caris Life Sciences in the 4th quarter valued at approximately $1,584,000. Finally, TD Waterhouse Canada Inc. acquired a new stake in shares of Caris Life Sciences in the 4th quarter valued at approximately $2,498,000.

Caris Life Sciences Price Performance

The stock has a market capitalization of $4.56 billion and a price-to-earnings ratio of -2.12. The company's 50 day simple moving average is $19.15. The company has a debt-to-equity ratio of 0.66, a current ratio of 7.85 and a quick ratio of 7.35.

Caris Life Sciences (NASDAQ:CAI - Get Free Report) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.27. Caris Life Sciences had a net margin of 3.75% and a return on equity of 102.71%. The firm had revenue of $292.89 million for the quarter, compared to analyst estimates of $281.00 million. During the same period in the prior year, the firm posted ($1.73) earnings per share. The company's quarterly revenue was up 125.4% compared to the same quarter last year. Analysts anticipate that Caris Life Sciences, Inc. will post 0.12 EPS for the current fiscal year.

About Caris Life Sciences

Caris Life Sciences NASDAQ: CAI is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.